OSRH
Bellevue Life Sciences Acquisition Corp (OSRH)
Healthcare • NASDAQ • $0.34-6.65%
- Symbol
- OSRH
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.34
- Daily Change
- -6.65%
- Market Cap
- $13.75M
- Trailing P/E
- 13.06
- Forward P/E
- N/A
- 52W High
- $1.71
- 52W Low
- $0.37
- Analyst Target
- $10.00
- Dividend Yield
- N/A
- Beta
- 0.61
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. The company was formerly known as OSR Holdings, Inc…
Company websiteResearch OSRH on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.